Abacterial prostatitis (CPPS)

What is abacterial prostatitis (CPPS)?

Abacterial prostatitis, medically referred to as Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS), is a chronic pain syndrome in the male pelvic area that occurs without detectable bacterial infection. The focus is not on a classic inflammatory process of the prostate but on a complex interplay of pain processing, neural mechanisms, and functional disorders.

Definition and classification

According to the classification of the National Institutes of Health (NIH), CPPS belongs to category III of prostatitis syndromes.

• Chronic pain in the pelvic area
• Duration of at least 3 months
• No detection of disease-causing bacteria

This form accounts for over 90% of all prostatitis diagnoses and is by far the most common variant. Within CPPS, further distinctions are made:

• Type IIIA (inflammatory): increased inflammatory cells detectable
• Type IIIB (non-inflammatory): no signs of inflammation

However, the crucial point is: neither inflammatory cells nor bacteria reliably correlate with symptom severity.

Distinction from bacterial prostatitis

In this context, the term "prostatitis" is even misleading, as it implies inflammation that is often not present. Modern guidelines therefore increasingly recommend the term "primary prostate pain syndrome."

CPPS as a pain syndrome – a modern approach

Current guidelines of the European Association of Urology (EAU) no longer consider CPPS as an isolated prostate disease but as part of a broader concept:

The focus is on:

• pain as an independent disease
• no clearly detectable organic cause
• Involvement of multiple systems:
• Nervous system
• Musculature (pelvic floor)
• Urinary tract
• Psychological factors

Chronic pain is understood here as an independent pathophysiological process that can develop regardless of an initial cause.

Pathophysiology: Why does CPPS develop?

The exact causes are not fully understood, but current studies show a clear pattern:

Central sensitization

The nervous system reacts hypersensitively to stimuli:

• pain is perceived more intensely
• even harmless stimuli can trigger pain

neuroinflammation

• activation of immune cells in the tissue
• release of inflammatory mediators
• increased irritation of nerve fibers

Dysregulation of the autonomic nervous system

• Disorders in bladder function and muscle tone
• Impact on sexual function

Pelvic floor dysfunction

• Muscle tension
• Trigger points in the pelvic area

Psychosocial factors

• Stress, anxiety, and pain processing significantly influence the course
• Pain intensity strongly correlates with psychological stress

Clinical significance

CPPS is not a rare condition, but:

• concerns men of all age groups
• often under 50 years of age
• causes a significant reduction in quality of life

Studies show that the burden is comparable to chronic diseases such as:

• diabetes
• chronic back pain

In addition, the course is often:

• prolonged
• episodic
• very individual differences

Why is CPPS so difficult to treat?

A key reason lies in the heterogeneous nature of the disease:

• There is no single cause
• Symptoms vary greatly between patients
• classic therapies (e.g., antibiotics) often do not work

Therefore, today it is accepted that CPPS is not a single disease entity but a syndrome with different cause profiles. This understanding forms the basis for modern therapeutic approaches – especially multimodal concepts that address multiple mechanisms simultaneously.

Why is CPPS not a typical inflammation of the prostate?

Chronic abacterial prostatitis (CPPS) is often interpreted as “prostate inflammation.” However, this assumption is medically untenable, as no infectious or classic inflammatory cause can be detected in the majority of affected individuals.

No correlation between inflammation and symptoms

A central argument against the classic inflammation hypothesis is the lack of correlation between objective findings and symptoms:

• Inflammatory cells may be present – but do not have to be
• Patients without evidence of inflammation often have equally severe pain
• symptom intensity is independent of inflammation parameters

It follows that inflammation is not the causal driver of the symptoms.

The term “prostatitis” is misleading

The medical term “-itis” by definition requires inflammation. However, this is usually not the case with CPPS.

The term has evolved historically but is pathophysiologically imprecise. More accurate are terms from modern guidelines such as:

• Prostate pain syndrome
• or more generally: chronic pelvic pain syndrome

Therapy failure of classic inflammatory approaches

Another indication comes from clinical practice:

• Antibiotics often show no lasting effect
• anti-inflammatory drugs often have limited effect
• Effects are usually temporary or inconsistent

If CPPS were primarily an inflammation, these therapies would have to be significantly more reliable.

Multifactorial rather than inflammatory cause

Current evidence shows that CPPS cannot be explained by a single cause. Instead, it is a multifactorial condition involving various systems:

• functional disorders in the pelvic area
• changes in pain processing
• muscular dysfunctions
• psychosocial influencing factors

These factors can trigger and maintain symptoms – even without classic inflammation.

Clinical significance of differentiation

The incorrect classification as inflammation has concrete consequences:

• Repeated, often ineffective antibiotic therapies
• Delay in effective therapeutic approaches
• Chronicity of symptoms

Correct classification as a pain syndrome, on the other hand, enables more targeted, individually tailored treatment.

What causes and mechanisms are behind CPPS?

Chronic abacterial prostatitis (CPPS) does not arise from a single cause but from a complex interplay of various biological and functional processes. Often, a nonspecific trigger such as a previous infection, mechanical irritation, or persistent stress initiates the condition. However, over time, the pain process becomes self-sustaining, so symptoms can persist even without a clearly identifiable cause. A central role is played by so-called central sensitization: the nervous system becomes hypersensitive, processes stimuli more intensely, and interprets even minor signals as pain. At the same time, local changes occur in the tissue, such as neurogenic inflammatory processes where inflammatory mediators are released without a classic bacterial infection being present. These processes lead to sensitization of pain receptors and a lowered stimulus threshold.

In addition, functional disorders of the nervous system and pelvic floor muscles contribute to maintaining the symptoms. Dysregulated control can lead to increased muscle tension, changes in blood flow, and heightened perception of pressure or pain. Psychoneurobiological factors also significantly influence the course: stress, anxiety, or increased focus on pain can further amplify signal processing in the brain. Modern concepts like the UPOINT system illustrate that CPPS affects multiple levels simultaneously – from urological and neurological to muscular and psychosocial factors. Therefore, it is crucial to understand that CPPS develops from a self-reinforcing cycle in which nerve activity, muscle tension, and pain processing influence each other and contribute to chronicity.

What symptoms are typical for chronic pelvic pain syndrome?

Chronic pelvic pain syndrome (CPPS) is characterized by a complex set of symptoms, with pain in the pelvic area being the primary complaint, often accompanied by functional and autonomic symptoms. Typically, the symptoms persist over a longer period – usually more than three months – and can vary in intensity. The pain is described differently by those affected, such as dull, pulling, burning, or stabbing, and can spread to various regions, including the perineum, lower abdomen, testicles, penis, or lower back. A particularly characteristic feature is that the pain is not constantly tied to one structure but can migrate or appear diffusely.

In addition to pain, urinary complaints often occur, such as increased urge to urinate, difficulty urinating, or the feeling of incomplete bladder emptying. Sexual dysfunctions are also typical, such as pain during or after ejaculation and reduced sexual satisfaction. Many patients also report increased muscle tension in the pelvic floor, which can intensify the pain. Furthermore, the psychological component plays a crucial role: chronic pain is often accompanied by stress, inner tension, or exhaustion, which in turn affects pain processing. Overall, CPPS is not just a local pain problem but a complex syndrome that affects multiple body systems simultaneously and can manifest very differently in individuals.

How does CPPS affect quality of life and sexual function?

Chronic pelvic pain syndrome (CPPS) has a significant impact on the quality of life of those affected, as it is associated not only with persistent pain but also with functional, emotional, and social limitations. Studies show that the quality of life of patients with CPPS is sometimes as severely impaired as in other chronic diseases, such as metabolic or cardiovascular diseases. Particularly distressing is the unpredictability of the symptoms: pain episodes can fluctuate, intensify, or radiate to new body areas, leading to a constant feeling of uncertainty and loss of control.

A key factor in the reduced quality of life is the close connection between pain, psychological stress, and everyday functioning. Chronic pain often leads to exhaustion, concentration problems, and limitations in professional life. At the same time, stress, anxiety, or depressive moods intensify pain processing, creating a burdensome cycle. Studies show that especially pain intensity and psychological factors largely determine how severely quality of life is impaired.

Sexual function is also significantly impaired in many affected individuals. Typical complaints include pain during or after ejaculation, reduced sexual desire, and decreased satisfaction during intercourse. These symptoms can be physically distressing but often also affect self-image and the experience of partnership. Studies show that men with CPPS suffer significantly more often from sexual function impairments than healthy comparison groups. Additionally, the symptoms can also affect the partner, for example through pain during intercourse or reduced sexual activity within the relationship.

Another central aspect is the psychosocial dimension of the condition. Chronic pain in the intimate area is often associated with shame, withdrawal, and reduced life satisfaction. Many affected individuals avoid social activities or intimate situations out of fear of pain or worsening symptoms. At the same time, the lack of a clear cause of the condition can lead to frustration, especially if previous therapy attempts were unsuccessful.

Overall, it is evident that CPPS goes far beyond a purely physical symptom pattern. The condition affects central areas of life – from physical performance to emotional stability to sexuality and partnership. This comprehensive understanding is crucial to adequately treat the condition and sustainably improve the quality of life of those affected.

How is CPPS treated according to current guidelines?

The treatment of chronic pelvic pain syndrome (CPPS) according to current guidelines is not monocausal but part of a multimodal, individualized therapy concept. The background is that CPPS is understood as a complex pain syndrome with various influencing factors. Accordingly, the therapy aims to address multiple mechanisms simultaneously – physical, neurological, and psychosocial.

The guidelines of the European Association of Urology (EAU) explicitly emphasize that purely symptom-oriented or one-sided treatment is usually insufficient. Instead, a structured approach is recommended that is based on the individual symptoms and the clinical profile of the patient.

Multimodal therapy approach as standard

The focus of treatment is the combination of different therapy forms. These can be weighted differently depending on the severity of symptoms but typically include:

• medication therapy
• physical and functional measures
• psychological and behavioral approaches

The goal is not only to reduce pain but also to improve quality of life and functional limitations.

Medication Therapy

Drug treatment is based on the symptoms present and includes several groups of active ingredients:

• Alpha-blockers: can improve urinary symptoms
• Nonsteroidal anti-inflammatory drugs (NSAIDs): short-term pain relief
• Neuromodulators: influence on pain processing in the nervous system
• Phytotherapeutics: e.g., quercetin with anti-inflammatory effects

However, effectiveness is often inconsistent and varies individually, which is why medications rarely suffice as sole therapy.

Physiotherapy and pelvic floor treatment

A central part of the guidelines is the treatment of functional disorders, especially of the pelvic floor muscles:

• Targeted pelvic floor training
• Manual therapy and trigger point treatment
• Relaxation techniques

These measures can help reduce muscle tension and sustainably improve pain symptoms.

Neuromodulatory and complementary methods

For therapy-resistant cases, further options are considered:

• Neuromodulation
• Acupuncture
• Biofeedback

These methods aim to regulate disturbed signal processing in the nervous system and reduce pain.

UPOINT system as a therapy guide

An essential tool for structuring treatment is the so-called UPOINT system. Symptoms are divided into different categories to enable targeted therapy:

Role of antibiotics

Guidelines clearly emphasize:

• Antibiotics are only useful when an infection is confirmed
• In CPPS without infection, their benefit is not proven

This is a key point because many patients have previously been treated multiple times with antibiotics – often without success.

Which medications help with abacterial prostatitis?

The drug treatment of abacterial prostatitis (CPPS) is complex and symptom-oriented, as there is no single cause. Guidelines therefore do not recommend a standardized active ingredient but the targeted use of different drug groups – depending on the individual symptom profile. It is important that medications are usually not used in isolation but as part of a multimodal therapy concept.

A central approach is to address different pathophysiological mechanisms simultaneously. For example, alpha-blockers can be helpful for predominant urinary symptoms, while anti-inflammatory substances mainly relieve pain in the short term. Neuromodulators, on the other hand, directly affect pain processing and are especially used in chronic cases. Plant-based active ingredients like quercetin also show significant symptom improvement in studies and represent a well-tolerated supplement.

It is also important to clearly distinguish from bacterial prostatitis: Antibiotics are not routinely indicated without pathogen detection, as their effectiveness in this context is not sufficiently proven.

Classification of drug therapy

Existing evidence shows that no single medication can reliably treat all symptoms of CPPS alone. Instead, patients benefit from an individualized combination based on the dominant symptoms.

This also explains why classic monotherapies often are not sufficient: CPPS affects multiple systems simultaneously – the nervous system, muscles, and functional processes in the pelvic area. Medications can influence individual components but rarely cover the entire syndrome.

Role of local therapeutic approaches

In recent years, local therapies have increasingly come into focus, especially in chronic cases. These aim to:

• To deliver active ingredients directly to the site of symptoms
• to avoid systemic side effects
• To specifically support mucous membranes and tissues, e.g. CANNEFF SUP Suppositories

This provides an important therapeutic complement to classic systemic medications.

Why is a multimodal therapy approach crucial for CPPS?

A multimodal therapeutic approach is crucial in CPPS because the condition cannot be attributed to a single cause but affects multiple systems simultaneously – especially the nervous system, pelvic floor muscles, and pain processing. Individual treatments usually address only one aspect of the symptoms and remain insufficient in the long term. Only the combination of medication, physiotherapy, and psychological measures makes it possible to specifically influence the different mechanisms and break the self-reinforcing pain cycle. Guidelines therefore explicitly recommend an individually tailored, multimodal therapy to achieve a sustainable improvement in symptoms and quality of life.

Why do many treatments for CPPS not have lasting effects?

Many treatments for CPPS show only short-term or insufficient effects because they often do not consider the actual complexity of the disease. CPPS is not a uniform condition with a clear cause but a multifactorial pain syndrome involving several mechanisms simultaneously – including central pain processing, muscular dysfunctions, and functional disorders in the urogenital tract. If only one of these factors is treated, others remain active and can maintain the symptoms.

Another crucial point is the chronification of pain. Through processes like central sensitization, pain can detach from its original cause and persist independently. In such cases, classic therapies targeting an assumed cause – such as antibiotics or purely anti-inflammatory drugs – often fall short. Additionally, CPPS patients show very different symptom profiles. Without individual therapy adjustment, treatment often remains nonspecific and ineffective.

Psychosocial factors also play an important role: stress, anxiety, or increased pain focus can intensify symptoms and affect therapy success. If these aspects are ignored, even an initially successful treatment can lose effectiveness over time. Overall, it becomes clear that CPPS requires a holistic approach – lack of individualization and single-cause therapy approaches are the most common reasons for missing or unsustainable treatment success.

What new treatment options are available for CPPS?

The treatment of chronic pelvic pain syndrome (CPPS) is increasingly moving away from classic, purely symptom-oriented approaches toward targeted, mechanism-based therapies. New treatment options focus especially where central pain processing, neurogenic inflammation, and functional disorders play a role. The goal is not only to relieve symptoms in the short term but to intervene in the disease mechanisms in the long term.

An important advancement lies in the increased consideration of the nervous system. Neuromodulatory methods aim to regulate disturbed pain processing. These include both medicinal approaches and non-invasive methods such as biofeedback or transcutaneous electrical nerve stimulation (TENS). Neuromodulation via external devices is also increasingly being studied, especially in therapy-resistant cases.

At the same time, local therapy approaches are gaining importance. These allow targeted treatment directly in the affected tissue without burdening the entire organism. Rectal or topical applications can exert anti-inflammatory and protective effects on the mucosa while simultaneously reducing the local pain response. Especially in the context of chronic conditions, such approaches offer an advantage as they avoid systemic side effects and can be applied continuously.

Another innovative area is the targeted influence on the endocannabinoid system. This plays a central role in regulating pain, inflammation, and tissue homeostasis. Cannabinoid-based approaches, especially with cannabidiol (CBD), show promising effects on pain reduction and inflammatory processes in initial studies, without psychoactive side effects. This creates a new therapeutic approach that can address both peripheral and central mechanisms.

Integrative approaches are also gaining importance. These include combinations of physiotherapy, psychological support, and modern pain therapies. Especially personalized therapy concepts based on individual symptom profiles (e.g., according to the UPOINT principle) show better results than standardized treatments.

Overall, these developments illustrate that the future of CPPS therapy lies in targeted, individualized, and multimodal treatment, where new technologies and biological approaches are used purposefully.

What role does the nervous system play in chronic prostatitis?

The nervous system plays a central role in the development and maintenance of chronic prostatitis (CPPS), as the complaints are largely characterized by disturbed pain processing. Through so-called central sensitization, nerve structures become hypersensitive, so that even minor or normal stimuli are perceived as pain. At the same time, pain signals can become self-sustaining and persist independently of an original cause. The autonomic nervous system is also often involved, which can lead to functional disorders in the pelvic area, such as during urination or sexual function. Overall, it becomes clear that CPPS is less a pure organ problem and is largely controlled by neurobiological processes.

Can the endocannabinoid system be used therapeutically?

The endocannabinoid system (ECS) represents a promising therapeutic approach for CPPS because it plays a central role in regulating pain, inflammation, and tissue homeostasis. It consists of endogenous cannabinoids, receptors (mainly CB1 and CB2), and enzymes and is significantly involved in modulating nerve activity and immune responses. Especially in chronic pain syndromes like CPPS, where neurogenic inflammatory processes and disturbed pain processing are prominent, the ECS offers a direct target for therapeutic interventions.

Activation of the endocannabinoid system can reduce the release of inflammatory mediators while modulating pain signal transmission in the nervous system. Cannabidiol (CBD) does not act directly as a classic receptor agonist but influences the system indirectly, among other things by inhibiting inflammatory processes and through cell-protective effects. This can positively affect both peripheral irritation in the tissue and central pain processing.

In particular, local applications are gaining importance in this context, as they enable targeted effects at the site of complaints. Initial clinical data show that cannabinoid-based therapies can contribute to a noticeable reduction in pain and functional complaints without causing significant systemic side effects. This opens up an innovative therapeutic approach through the endocannabinoid system, which simultaneously addresses multiple pathophysiological mechanisms of CPPS and integrates well into multimodal treatment concepts.

How effective are CANNEFF® SUP suppositories for CPPS according to the study?

The efficacy of CANNEFF® SUP suppositories with CBD and hyaluronic acid was investigated in an open pilot study with 16 patients with chronic abacterial prostatitis (CPPS) over 30 days. The results show a clinically relevant and significant improvement in symptoms, especially in the areas of pain and urinary symptoms.

The most important parameter, the NIH-CPSI score, improved on average by about −7 points, which is considered a significant symptom relief. The pain component also decreased significantly, while voiding symptoms (IPSS) also showed measurable improvement. Overall, over 80% of patients showed clinical improvement without reported side effects.

Compared to classic therapies such as alpha-blockers or herbal preparations, the efficacy is in a similar range, but with a crucial difference: the effect is local rather than systemic, which improves tolerability.

CANNEFF® SUP offers an effective, well-tolerated, and locally acting therapy option for CPPS. The results are promising but should be further confirmed by larger controlled studies. A larger clinical trial is currently underway.

How do CANNEFF® SUP suppositories compare to traditional therapies?

Compared to classic therapy approaches, CANNEFF® SUP suppositories with CBD and hyaluronic acid show comparable clinical efficacy but differ significantly in their mode of action and side effect profile.

Classic therapies such as alpha-blockers, analgesics, or phytotherapeutics typically achieve a reduction in the NIH-CPSI score of about −2 to −5 points in studies, with results often varying widely and not clinically relevant for all patients.

In contrast, CANNEFF® SUP in the pilot study shows an improvement of about −7 points, which is considered clearly clinically relevant and is at the upper range of typical therapy effects.

Another crucial difference lies in the consistency of the effect: While classic therapies often deliver inconsistent results and frequently only have short-term effects, the study data on CANNEFF® show a high response rate of over 80% with good tolerability.

Data show that CANNEFF® SUP can achieve not only a similar but sometimes higher effect size than established therapies. Particularly relevant is:

• the local mode of action (directly at the affected tissue)
• the combination of CBD (neuro- and anti-inflammatory) and hyaluronic acid (tissue protection)
• the very good safety profile without systemic burden

While classic medications often address only individual aspects of the disease, CANNEFF® acts simultaneously on multiple pathophysiological levels, which is crucial for a multifactorial syndrome like CPPS.

Who are rectal therapies for prostatitis suitable for?

Rectal therapies represent a targeted treatment option for chronic abacterial prostatitis (CPPS), especially for patients whose local symptoms are predominant or for whom systemic therapies are insufficiently effective or poorly tolerated. Due to the anatomical proximity to the prostate, they enable direct drug application to the affected area, achieving a high local concentration with minimal systemic exposure.

Rectal therapy approaches are particularly useful for patients with dominant pain symptoms in the pelvis, perineum, or pelvic floor, as local anti-inflammatory and pain-relieving effects can be specifically utilized here. Men with pronounced urinary symptoms or a feeling of pressure in the pelvis also often benefit, especially when these symptoms are related to functional or neurogenic processes.

Furthermore, rectal applications are suitable for patients who respond inadequately to classic drug therapies—such as alpha-blockers, NSAIDs, or antibiotics—or who experience side effects. Since rectal therapies generally act locally, they offer a well-tolerated alternative or complement within a multimodal treatment approach.

Another advantage is evident in chronic cases: rectal therapies can be used continuously and long-term without burdening the body systemically. This is especially relevant for CPPS, as the condition often persists over a longer period and sustainable symptom control is necessary.

Overall, rectal therapies are especially suitable for patients for whom targeted local treatment seems appropriate—either as a supplement to existing therapies or as an alternative option when therapy success is insufficient.

How to correctly use CANNEFF® suppositories?

CANNEFF® SUP Suppositories are applied rectally to enable targeted local effects in the area of the prostate and surrounding tissue. Correct application is crucial to achieve optimal effectiveness and to integrate the therapy well into daily life.

The application is usually once daily, preferably in the evening before going to sleep. At this time, physical activity is reduced, allowing the suppository enough time to dissolve and release the active ingredients locally.

Before use, hands should be washed thoroughly. The suppository is carefully removed from the packaging and then inserted tip first into the rectum. A relaxed body position—such as lying on the side with legs slightly bent—makes insertion easier. It is important to insert the suppository deep enough so that it does not slip out again.

After application, it is recommended to lie still for a few minutes to support absorption. Ideally, the bowel should have been emptied beforehand, as this improves the uptake of active ingredients and prolongs the duration of effect.

The duration of use depends on the individual symptoms but is often about 30 days in studies and practice. If needed, the application can be extended or repeated as part of a multimodal therapy concept.

Is CPPS curable or controllable in the long term?

According to current medical understanding, chronic pelvic pain syndrome (CPPS) is not considered fully curable in all cases, but it is well manageable in the long term in most cases. The key difference is that it is a complex pain syndrome where symptoms can become independent over time. Therefore, complete elimination of all symptoms is not always realistic, but significant and lasting improvement is very often achievable.

The course of CPPS varies individually and is often characterized by fluctuations. Many patients experience phases of significant improvement or almost complete relief from symptoms, followed by occasional relapses. Studies also show that some affected individuals experience spontaneous improvement over time even without intensive therapy. At the same time, the condition can become chronic with insufficient treatment and permanently impair quality of life.

Crucial for long-term success is a structured, multimodal treatment concept. By combining various therapeutic approaches—such as drug treatment, physiotherapy, stress management, and local therapies—the underlying mechanisms can be specifically influenced. The goal is to reduce pain, stabilize function, and avoid relapses as much as possible.

An important aspect is the active role of the patient. Regular exercise, targeted relaxation techniques, and conscious stress management can significantly contribute to stabilization. Understanding the disease itself also plays a role: patients who understand CPPS as a manageable pain syndrome often handle symptoms more confidently and benefit more from therapy.

Which strategies help in the long term with CPPS?

In the long term, patients with CPPS benefit primarily from a consistently multimodal approach that simultaneously considers multiple influencing factors. This includes an individually tailored combination of drug therapy, targeted pelvic floor physiotherapy, and measures to regulate pain processing. Additionally, stress management, regular exercise, and relaxation techniques play a central role, as psychological factors can significantly influence the course.

It is also important to continuously apply appropriate therapies, especially in chronic courses. Local treatment approaches can be usefully integrated here to specifically control symptoms. A long-term strategy with realistic goals is crucial: not complete cure, but stable symptom control and improvement in quality of life.

Sources

Zhang, Z. C., & Peng, J. (2013). Zhonghua nan ke xue = National journal of andrology, 19(7), 579–582. https://pubmed.ncbi.nlm.nih.gov/24386866/

Nickel, J. C., Alexander, R. B., Anderson, R., Berger, R., Comiter, C. V., Datta, N. S., Fowler, J. E., Krieger, J. N., Landis, J. R., Litwin, M. S., McNaughton-Collins, M., O'Leary, M. P., Pontari, M. A., Schaeffer, A. J., Shoskes, D. A., White, P., Kusek, J., Nyberg, L., & Chronic Prostatitis Collaborative Research Network Study Groups (2008). Category III chronic prostatitis/chronic pelvic pain syndrome: insights from the National Institutes of Health Chronic Prostatitis Collaborative Research Network studies. Current urology reports, 9(4), 320–327. https://doi.org/10.1007/s11934-008-0055-7

AU Guidelines on Chronic Pelvic Pain D. Engeler (Chair), A.P. Baranowski, B. Berghmans, A.M. Cottrell, J. Dütschler, I. Flink, I.M. Grzybowska, B. Parsons, K. Petersen, R.A. Pinto, V. Tidman, B. Vyawahare Guidelines Associates: P. Abreu-Mendes, R. Husein, A. Nic an Riogh Patient Advocates: J. Birch, M.L. van Poelgeest https://uroweb.org/guidelines/chronic-pelvic-pain/summary-of-changes/2025